[Strategies for combating resistances in HIV therapy--an exemplifying case].
Stoehr
A
A
Institut für interdisziplinäre Infektiologie und Immunologie GmbH, Hamburg.
D000368:Aged; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D017326:Clinical Trials, Phase III as Topic; D024921:Drug Resistance, Multiple, Viral / Q000187:drug effects*; D004359:Drug Therapy, Combination; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000009:adverse effects / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008134:Long-Term Care; D008297:Male; D010446:Peptide Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D019562:Viral Load
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide
Antiretrovirale Kombinationstherapie. Neuer Wirkstoff hält HI-virus in Schach.